207 related articles for article (PubMed ID: 15901003)
1. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
2. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
3. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
4. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
Korfel A; Thiel E; Martus P; Möhle R; Griesinger F; Rauch M; Röth A; Hertenstein B; Fischer T; Hundsberger T; Mergenthaler HG; Junghanß C; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Roth P; Bamberg M; Pietsch T; Weller M
Neurology; 2015 Mar; 84(12):1242-8. PubMed ID: 25716362
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate for primary CNS lymphoma in the elderly.
Ng S; Rosenthal MA; Ashley D; Cher L
Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253
[TBL] [Abstract][Full Text] [Related]
7. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
10. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
11. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
12. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
14. Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
Abdelsalam M; El-Husseiny G; Akhtar S; Khafaga Y; Al-Shabana M; AlHusaini H; El Weshi A; Rahal M; Maghfoor I
Hematol Oncol Stem Cell Ther; 2010; 3(3):128-34. PubMed ID: 20890070
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.
Blay JY; Conroy T; Chevreau C; Thyss A; Quesnel N; Eghbali H; Bouabdallah R; Coiffier B; Wagner JP; Le Mevel A; Dramais-Marcel D; Baumelou E; Chauvin F; Biron P
J Clin Oncol; 1998 Mar; 16(3):864-71. PubMed ID: 9508167
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.
Sung KH; Lee EH; Kim YZ
J Korean Med Sci; 2011 Apr; 26(4):551-60. PubMed ID: 21468264
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment.
Herrlinger U; Schabet M; Brugger W; Kortmann RD; Kanz L; Bamberg M; Dichgans J; Weller M
Cancer; 2001 Jan; 91(1):130-5. PubMed ID: 11148569
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.
Omuro AM; Taillandier L; Chinot O; Carnin C; Barrie M; Hoang-Xuan K
J Neurooncol; 2007 Nov; 85(2):207-11. PubMed ID: 17896079
[TBL] [Abstract][Full Text] [Related]
19. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
